Bi, Yan
Lu, Song
Tang, Jiani
Du, Liying
Ji, Linong
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes: Analysis of SURPASS-AP-Combo by Different Subgroups
https://doi.org/10.1007/s13300-024-01561-2
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 12 December 2023
Accepted: 29 February 2024
First Online: 18 March 2024
Declarations
:
: Linong Ji reports having received consulting or lecture fees from Eli Lilly and Company, Novo Nordisk, Merck, Bayer, Sanofi-Aventis, Roche, MSD, Metronics AstraZeneca, Boehinger Ingelheim, Abbott, Haisco Pharmaceutical. Yan Bi and Song Lu have nothing to disclose. Jiani Tang and Liying Du are employees of Eli Lilly and Company, and hold equity in Eli Lilly and Company.
: The study protocol was approved by Ethics Review Boards at each site and written informed consent was collected from all participants. The study was conducted in accordance with the principles of international ethics guidelines, including the Declaration of Helsinki, and applicable local laws and regulations.